Drug intelligence / Profile preview

Kunling Wan

Development stage: Unknown
Lead developer: Liaoning Hancaotang Traditional Chinese Medicine
Modality: Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Kunling Wan is a standardized traditional Chinese medicine (TCM) patent drug composed of 31 herbal ingredients. It has been approved in China since 2004 for various gynecological and reproductive health conditions. Developed and manufactured by Liaoning Hancaotang Traditional Chinese Medicine, the formulation is primarily used to treat polycystic ovary syndrome (PCOS), diminished ovarian reserve (DOR), and infertility. According to TCM principles, it addresses kidney deficiency, qi stagnation, and blood stasis. Clinically, it is reported to improve ovarian follicular development, enhance ovarian function, and increase endometrial receptivity, thereby improving pregnancy outcomes.

Brand names: Kunling Wan
Other names: Kunling Pill坤灵丸

Beyond the preview

Go deeper on Kunling Wan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kunling Wan.

Explore the full profile